Oligonucleotide therapeutics — Novel cardiovascular targets (original) (raw)

Nature Medicine volume 3, pages 834–835 (1997)Cite this article

Antisense approaches and decoy strategies are at the heart of new pre-clinical studies (pages 894–903).

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Stein, C.A. Does antisense exist? Nature Med. 1, 1119–1121 (1995).
    Article CAS Google Scholar
  2. Guvakova, M.A., Yakubov, L.A., Vlodavsky, I., Tonkinson, J.L. & Stein, C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620–2627 (1995).
    Article CAS Google Scholar
  3. Suzuki, J. et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotides. Nature Med. 3, 900–903 (1997).
    Article CAS Google Scholar
  4. Morishita, R. et al. In vivo transfection of cis element “decoy” against NF-κB binding site prevented myocardial infarction as gene therapy. Nature Med. 3, 894–899 (1997).
    Article CAS Google Scholar
  5. Simons, M., Edelman, E., DeKeyser, J., Langer, R. & Rosenberg, R. Antisense c-myb oligonucleotides inhibit intirnal arterial smooth muscle cell accumulation in vivo. Nature 359, 67–70 (1992).
    Article CAS Google Scholar
  6. Shi, Y. et al. Transcatheter delivery of c-myc anti-sense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90, 944–951 (1994).
    Article CAS Google Scholar
  7. Morishita, R. et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc.Natl.Acad.Sci.USA 90, 8474–8478 (1993).
    Article CAS Google Scholar
  8. Roque, F. et al. Safety of intracoronary administration of c-myc antisense after PTCA. J. Am. Coll. Cardiol. 29, 317A (197) Abstr.
    Google Scholar
  9. Billingham, M.E. Cardiac transplant atherosclerosis. Transplantation Proceedings 19, 19–25 (1987).
    CAS PubMed Google Scholar
  10. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343, 311–322 (1994).
  11. Beg, A.A. & Baltimore, D. An essential role for NF-κB in preventing TNF-induced cell death. Science 274, 782–784 (1996).
    Article CAS Google Scholar
  12. Granger, H.J. et al. Molecular and cellular basis of myocardial angiogenesis. Cell. Mol. Biol. Res. 40, 81–85 (1994).
    CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, 02135, USA
    Jeffrey M. Isner

Authors

  1. Jeffrey M. Isner
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Isner, J. Oligonucleotide therapeutics — Novel cardiovascular targets.Nat Med 3, 834–835 (1997). https://doi.org/10.1038/nm0897-834

Download citation